Dr. David R Minor MD
Oncologist | Medical Oncology
2100 Webster St #326 San Francisco CA, 94115About
Dr. David Minor is an oncologist practicing in San Francisco, CA. Dr. Minor specializes in the care and treatment of patients with cancer. As an oncologist, Dr. Minor manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Oncologists will care for their patients throughout the course of the disease. Types of oncologists include medical oncologists, surgical oncologists, radiation oncologists, gynecologic oncologists, pediatric oncologists and hematologist oncologists.
Education and Training
Univ of Ca, San Francisco, Sch of Med, San Francisco Ca 1974
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM
Provider Details
Expert Publications
Data provided by the National Library of Medicine- A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
- Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
- Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.
- Risk of venous thromboembolism with bevacizumab in cancer patients.
- Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
- Risk of bleeding not increased by sorafenib or sunitinib.
- Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of
- Risk of arterial thrombosis not increased by sorafenib or sunitinib.
- Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
- gp100 peptide vaccine in melanoma.
- Bevacizumab advanced melanoma (BEAM) was a positive trial.
- Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
- Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.
Fellowships
- Yale - New Haven Hospital
Dr. David R Minor MD's Practice location
Dr. David R Minor MD's reviews
Write ReviewRecommended Articles
- Colon Cancer
What is colon cancer?Colon cancer is cancer of the large intestine, also known as the colon. If the last segment of the colon, the rectum, has a cancerous growth, it is known as rectal carcinoma. These two conditions are collectively referred to as colorectal cancer.Carcinoma of the colon is the...
- Why We Can’t Treat All Ovarian Cancer the Same Way
Over the last three decades, ovarian cancer survival rates have seen very little improvement. The current five-year survival rate for ovarian cancer is 43%, a low percentage that is a result of the fact that this type of cancer is difficult to detect and often goes undiagnosed until it has reached...
- What Causes Colon Cancer?
As with any cancer, genetic factors play a role in colon cancer as well. However, greater than 75% to 90% of the population develops colon cancer with little or no genetic risk. This means that genetic factors play only a minor role in colon cancers.What are the genetic factors that predispose you...
- Unborn Baby Saved Mother from Ovarian Cancer
Bringing a child into the world is monumental for anyone, and having a baby changes a mother's life forever. However, in the case of Karly Miller, her baby literally saved her life.Diagnosis during pregnancyKarly Miller was at the 19-week mark during her pregnancy when she was diagnosed with ovarian...
- Overcoming Lymphoma: A South Philly Student's Story
In April of 2018, 18-year-old Alexis Carine was diagnosed with Hodgkin’s lymphoma (HL), a blood cancer that begins in the lymphatic system. Her diagnosis was stage II HL, a cancer found in two or more lymph node areas, and both are either above or below the diaphragm (the muscle located just...
- What to Avoid if You Have Leukemia
Leukemia, known as the cancer of the blood, can progress either acutely, which the is rapid and sudden onset of the disease, or chronically, which is a slow manifestation of symptoms over a period of time. There are several complications of leukemia that may arise which can hinder the patient’s...
Nearby Providers
- Dr. John W Park MD1600 Divisadero St San Francisco CA 94115
- Dr. Mark M Moasser M.D.1600 Divisadero St San Francisco CA 94115
- Dr. Thierry M. Jahan MD1600 Divisadero St San Francisco CA 94115
- Dr. Bertrand Y Tuan M.D.2100 WEBSTER ST STE 225 SAN FRANCISCO CA 94115
- Dr. Hope S. Rugo MD1600 Divisadero St San Francisco CA 94115
- Dr. Alan M Kramer MD2100 Webster St San Francisco CA 94115